FCGR3A and cancer: There are three primary approaches directing NK cells for cancer treatment: 1) employing NK cell antibody-dependent cellular cytotoxicity (NK cell ADCC), which is initiated through the Fc receptor CD16a on NK cells and directed by a monoclonal antibody (mAb); 2) genetically engineering CAR-NK cells that specifically target tumor antigens using the CAR and become activated; 3) developing recombinant proteins, known as NK cell engagers (NKCE), that bring tumor and NK cells into proximity and activate the NK cells (Figure 1).